Cited 0 times in
Baseline and on-treatment HBcrAg levels as predictors of HBeAg seroconversion in chronic hepatitis B patients treated with antivirals
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 유성환 | - |
dc.contributor.author | 이관식 | - |
dc.contributor.author | 이정일 | - |
dc.contributor.author | 이현웅 | - |
dc.date.accessioned | 2023-05-31T05:54:31Z | - |
dc.date.available | 2023-05-31T05:54:31Z | - |
dc.date.issued | 2023-01 | - |
dc.identifier.issn | 1352-0504 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/194297 | - |
dc.description.abstract | HBeAg seroconversion is an important treatment endpoint. We aimed to identify predictors of seroconversion using serum HBsAg and hepatitis B core-related antigen (HBcrAg) in HBeAg-positive patients treated with nucleos(t)ide analogs (NAs). Data and samples from 70 HBeAg-positive patients treated with entecavir or tenofovir between January 2007 and December 2017 were retrospectively analysed. The mean follow-up period was 11 years. The predictive power for HBeAg seroconversion of HBcrAg levels at baseline and 2 years after antiviral therapy was determined using receiver operating curve analysis. Twenty-one patients (30%) achieved HBeAg seroconversion at a mean of 28 (range, 12–84) months after antiviral treatment. The median baseline HBcrAg and HBsAg levels were 6.9(5.7–7.0) vs. 5.8(5.5–6.5) log10U/mL (p = .006), 4.9(4.5–5.1) vs. 4.5(4.1–5.0) log10IU/mL (p = .044) in the no seroconversion group and seroconversion group, respectively. In the multivariate analysis, the serum HBcrAg levels at baseline and 2 years after antiviral therapy were predictive factors for HBeAg seroconversion ([HR]; 0.326; [CI], 0.111–0.958; p = .042 and HR, 0.4555; CI, 0.211–0.984; p = .045). HBcrAg levels≤6.5log10U/mL at baseline and ≤5.3log10U/ mL at 2 years after antiviral therapy had sensitivities of 53.1% and 69.8%, specificities of 95.2% and 70.6%, positive predictive values of 82.6% and 50.0%, and negative predictive values of 82.6% and 84.5%, respectively, with AUROCs of 0.712 (95%CI, 0.596–0.830) and 0.745 (95%CI, 0.599–0.891) for predicting HBeAg seroconversion. In chronic hepatitis B patients treated with NAs, HBcrAg levels≤6.5log10U/mL at baseline and ≤5.3log10U/mL at 2 years after antiviral therapy were useful predictive factors of HBeAg seroconversion. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.language | English | - |
dc.publisher | Blackwell Scientific Publications | - |
dc.relation.isPartOf | JOURNAL OF VIRAL HEPATITIS | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Antiviral Agents* / therapeutic use | - |
dc.subject.MESH | DNA, Viral / analysis | - |
dc.subject.MESH | Hepatitis B Core Antigens | - |
dc.subject.MESH | Hepatitis B Surface Antigens | - |
dc.subject.MESH | Hepatitis B e Antigens | - |
dc.subject.MESH | Hepatitis B virus / genetics | - |
dc.subject.MESH | Hepatitis B, Chronic* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Retrospective Studies | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Baseline and on-treatment HBcrAg levels as predictors of HBeAg seroconversion in chronic hepatitis B patients treated with antivirals | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Soo Young Hwang | - |
dc.contributor.googleauthor | Sung Hwan Yoo | - |
dc.contributor.googleauthor | Hye Young Chang | - |
dc.contributor.googleauthor | Sora Kim | - |
dc.contributor.googleauthor | Jung Il Lee | - |
dc.contributor.googleauthor | Kwan Sik Lee | - |
dc.contributor.googleauthor | Young Youn Cho | - |
dc.contributor.googleauthor | Kim Hyung Joon | - |
dc.contributor.googleauthor | Hyun Woong Lee | - |
dc.identifier.doi | 10.1111/jvh.13765 | - |
dc.contributor.localId | A05883 | - |
dc.contributor.localId | A02666 | - |
dc.contributor.localId | A03122 | - |
dc.contributor.localId | A03292 | - |
dc.relation.journalcode | J01928 | - |
dc.identifier.eissn | 1365-2893 | - |
dc.identifier.pmid | 36321949 | - |
dc.identifier.url | https://onlinelibrary.wiley.com/doi/10.1111/jvh.13765 | - |
dc.subject.keyword | hepatitis B | - |
dc.subject.keyword | hepatitis B core-related antigen | - |
dc.subject.keyword | hepatitis B e antigen seroconversion | - |
dc.subject.keyword | hepatitis B surface antigen | - |
dc.subject.keyword | nucleos(t)ide analog | - |
dc.contributor.alternativeName | Yoo, Sung Hwan | - |
dc.contributor.affiliatedAuthor | 유성환 | - |
dc.contributor.affiliatedAuthor | 이관식 | - |
dc.contributor.affiliatedAuthor | 이정일 | - |
dc.contributor.affiliatedAuthor | 이현웅 | - |
dc.citation.volume | 30 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 39 | - |
dc.citation.endPage | 45 | - |
dc.identifier.bibliographicCitation | JOURNAL OF VIRAL HEPATITIS, Vol.30(1) : 39-45, 2023-01 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.